Loews Stock News

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable September 1, 2026 to shareholders of record as of the close of business on August 19, 2026. Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality, and packaging industries.

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) today released its second quarter 2026 financial results. Second Quarter 2026 highlights: Loews Corporation reported net income of $444 million, or $2.16 per share, in the second quarter of 2026, compared to $391 million, or $1.87 per share, in the second quarter of 2025.

As EQB prepares to close its Acquisition of PC Financial on July 1, 2026, the company announces a strengthened leadership team drawing on talent from both organizations, positioning EQB for a differentiated phase of growth Key appointments include: Ian Hanning from PC Financial to SVP, Credit Cards and Loyalty Mark Snyder from PC Financial to SVP, Credit Risk and Data Analytics Michaela Garfiel...

Transformative partnership between Tsuut'ina Nation, Taza Development Corp. and Real Canadian Superstore advances as opening preparations get underway Transformative partnership between Tsuut'ina Nation, Taza Development Corp. and Real Canadian Superstore advances as opening preparations get underway

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- In the latest edition of its Food Inflation Report, Loblaw is pleased to provide context around what's impacting food prices – now and into the future. This report follows Statistics Canada's release of data for the month of April.

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Ahead of Menstrual Health Day on May 28, Shoppers Foundation for Women's Health™ is proud to announce $300,000 in funding commitments over two years to support organizations advancing menstrual equity in Canada.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult patients with unresectable locally advanced o...

BRAMPTON, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Being an Insider is all about the thrill of discovery, that can't-wait-to-see-what's-next energy. Here at President's Choice, we're always pushing new taste possibilities.